Know Cancer

or
forgot password

A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy


Phase 2
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy


Inclusion Criteria:



- Patients with ER-positive locally advanced breast cancer or Metastatic Breast Cancer
(MBC). Postmenopausal women with locally advanced breast cancer or Metastatic Breast
Cancer whose disease has progressed during or after treatment with an aromatase
inhibitor. Part II: Postmenopausal women with locally advanced PIK3CA-mutant breast
cancer or PIK3CA-mutant MBC that has progressed during or after treatment with an AI.

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Patients must have measurable disease by RECIST v1.1 or bone-only disease

- Adequate hematologic and end-organ function

- Estrogen receptor-positive disease and HER2-negative disease

Exclusion Criteria:

- Prior treatment with fulvestrant, PI3K inhibitor, or mTOR inhibitor for advanced
breast cancer or MBC

- Prior treatment with > one cytotoxic chemotherapy regimens or experienced recurrent
or progressive disease on > two endocrine therapies for metastatic breast cancer

- History of malabsorption syndrome or other condition that would interfere with
enteral absorption

- History of clinically significant cardiac or pulmonary dysfunction

- Clinically significant history of liver disease

- Active uncontrolled autoimmune disease or active inflammatory disease

- Immunocompromised status

- Symptomatic hypercalcemia

- Need for current chronic corticosteroid therapy

- Pregnancy, lactation, or breastfeeding

- Known untreated or active central nervous system (CNS) metastases Other
protocol-defined inclusion/exclusion criteria may apply.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Progression-free survival (PFS) as assessed by the investigator per modified RECIST version 1.1

Outcome Time Frame:

until disease progression, up to 1 year

Safety Issue:

No

Principal Investigator

Gallia Levy, M.D., Ph.D.

Investigator Role:

Study Director

Investigator Affiliation:

Genentech

Authority:

United States: Food and Drug Administration

Study ID:

GDC4950g

NCT ID:

NCT01437566

Start Date:

October 2011

Completion Date:

September 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Hinsdale, Illinois  60521
Albany, Georgia  31701
Birmingham, Alabama  35294
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
McLean, Virginia  22101
Kansas City, Kansas  66160
Hackensack, New Jersey  07601
Boston, Massachusetts  
Charleston, South Carolina  
Washington, District of Columbia